KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor

Volume: 20, Issue: 10, Pages: 2035 - 2048
Published: Aug 10, 2021
Abstract
Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib (IM), a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST, and adjuvant therapy only delays recurrence in high-risk tumors. We hypothesized that GIST contains cells with primary IM resistance that may represent a reservoir for disease persistence. Here, we report a subpopulation of CD34+KITlow human GIST...
Paper Details
Title
KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor
Published Date
Aug 10, 2021
Volume
20
Issue
10
Pages
2035 - 2048
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.